N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 16, 2007, Pages 4599-4603

  Deur, Christopher ^a   Agrawal, Arun K ^a   Baum, Heidi ^a   Booth, John ^a   Bove, Susan ^a   Brieland, Joan ^a   Bunker, Amy ^a   Connolly, Cleo ^a   Cornicelli, Joseph ^a   Dumin, JoAnn ^a   Finzel, Barry ^a   Gan, Xinmin ^a   Guppy, Sheila ^a   Kamilar, Gregg ^a   Kilgore, Kenneth ^a   Lee, Pil ^a   Loi, Cho Ming ^a   Lou, Zhen ^a   Morris, Mark ^a   Philippe, Laurence ^a   Przybranowski, Sally ^a   Riley, Frank ^a   Samas, Brian ^a   Sanchez, Brian ^a   Tecle, Haile ^a   Wang, Ziqiang ^a   Welch, Kathryn ^a   Wilson, Michael ^a   Yates, Karen ^a   more..

^a PFIZER INC   (United States)

Author keywords

NMDA antagonist; Osteoarthritis; Pain

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRO (6,7 DICHLORO 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YL) NITRO ALKYLSULFONAMIDE; QUINOXALINE DERIVATIVE; UK 240455; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; IC 50; NONHUMAN; RAT; STROKE;

ANALGESICS; ANIMALS; AREA UNDER CURVE; BINDING SITES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PAIN; PROTEIN BINDING; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 34447340228     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.083     Document Type: Article

References (32)

1. Petrenko A.B., Yamakura T., Baba H., and Shimoji K. Anesth. Analg. 97 (2003) 1108
2. Coggeshall R.E., and Carlton S.M. Brain Res. Rev. 24 (1997) 28
3. McRoberts J.A., et al. Gastroenterology 120 (2001) 1737
4. McNearney T., Speegle D., Lawand N., Lisse J., and Westlund K. J. Rheumtol. 27 (2000) 739
5. McNearney T., Baethge B.A., Cao S., Alam R., Lisse J.R., and Westlund K.N. Clin. Exp. Immunol. 137 (2004) 621
6. Lawand N.B., Willis W.D., and Westlund K.N. Eur. J. Pharmacol. 324 (1997) 169
7. Westlund K.N., Sun Y.C., Sluka K.A., Dogherty P.M., Sorkin L.S., and Willis W.D. Brain Res. Rev. 17 (1992) 15
8. Du J., Zhou S., Coggeshall R.E., and Carlton S.M. Neuroscience 118 (2003) 547
9. Carlton S.M., and Coggeshall R.E. Brain Res. 820 (1999) 63
10. Internal studies found NMDA NR1 receptors distributed in human cartilage, human primary chondrocytes, human normal dermal fibroblasts primary cells, and human OA synovial primary fibroblasts. The NMDA NR1 subunit was also detected in rat synovial fat pad, rat bone, and rat chondrosarcoma.
11. Chizh B.A., and Headly P.M. Curr. Pharm. Des. 11 (2005) 2977
12. Gardoni F., and Di Luca M. Eur. J. Pharmacol. 545 (2006) 2
13. Chizh B.A., and Headly P.M. Curr. Pharm. Des. 11 (2005) 2977 and references therein
14. Lipton S. Nat. Rev. Drug Disc. 5 (2006) 160
15. Webster R., Cole S., Gedge J., Roffey S., Walker D., and Wild W. Xenobiotica 33 (2003) 541
16. Compounds 3a, 3c-f were prepared in a manner previously reported:. Fray M.J., Bull D.J., Carr C.L., Gautier E.C.L., and Mowbray C.E. J. Med. Chem. 44 (2001) 1951
17. Compound 3b was prepared from the known 5-chloro-2,3-diamino-nitrobenzene:. Keana J.F.W., et al. J. Med. Chem. 38 (1995) 4367
18. Cai S.X., Huang J.C., Espitia S.A., Tran M., Ilyin V.I., Hawkinson J.E., Woodward R.M., Weber E., and Keana J.F.W. J. Med. Chem. 40 (1997) 3679
19. Upton N., et al. Eur. J. Pharmacol. 553 (2006) 109
20. Kelder J., Grootenhuis D.J., Bayada D.M., Delbressine L.P.C., and Ploeman J.P. Pharm. Res. 16 (1999) 1514
21. Oral bioavailability and oral exposures were determined using Sprague-Dawley rats. Oral doses were measured at 5 mg/kg.
22. Lipinski C.A. Drug Discovery Today Technol. 1 (2004) 12
23. Lipinski C.A., et al. Adv. Drug. Deliv. Rev. 23 (1997) 3
24. Separation of the racemic compounds into their constituent atropisomers was achieved via SFC chromatography on a Chiracel AD-H column.
25. Eliel E., Wilen S.H., and Mander L.N. Stereochemistry of Organic Compounds (1994), John Wiley, New York 1119
26. Modeling was carried out based on the published X-ray structure data:. Furukawa H., and Gouaux E. EMBO J. 22 (2003) 2873 using the internal program, AGDOCK
27. Gehlhaar D.K., Verkhivker G.M., Rejto P.A., Sherman C.J., Fogel D.B., Fogel L.J., and Freer S.T. Chem. Biol. 2 (1995) 317
28. Gehlhaar, D.; Bouzida, D.; Rejto, P. A. In ACS Symposium Series 719: Rational Drug Design, Parrill, A. L. Reddy, M. R., Eds.; ACS Press, 1999, p 292.
29. The observed difference in plasma exposures for compounds 30 and 31 (the (S) and (R) atropisomers, respectively) is likely due to the slower rate of clearance observed for the (S)-atropisomer. The stereochemically based difference in rates of clearence is a phenomenon that has been reported previously:. Landoni M.F., Comas W., Mucci N., Anglarilli G., Bidal D., and Lees P. J. Vet. Pharmacol. Ther. 22 (1999) 349
30. Chen Y., Liu X.Q., Zhong J., Zhao X., Wang Y., and Wang G. Chirality 18 (2006) 799
31. The absolute stereochemistry of compound 34 was verified by single crystal X-ray crystallography.
32. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., and Hole K. Pain 51 (1992) 5